Research programme: CAR-T cell therapeutics - BioAtla/F1 OncologyAlternative Names: CAB CAR-T therapy
Latest Information Update: 17 Jan 2017
At a glance
- Originator BioAtla
- Class CAR-T cell therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours